医学
队列
抗合成酶综合征
预测模型
比例危险模型
接收机工作特性
回顾性队列研究
生存分析
死亡率
队列研究
死亡风险
风险评估
内科学
试验预测值
稳健性(进化)
预测建模
存活率
弗雷明翰风险评分
外部有效性
重症监护医学
推车
疾病严重程度
临床实习
推导
随机森林
作者
Shiyu Wu,H Cai,Yinli Zhang,Chen Zong,L Zhu,Xinxin Zhang,Yiran Chen,Yingfang Zhang,Chao Sun,Qi Pan,S Li,Xiaoming Shu,Xin Lu,G C Wang,Qinglin Peng
摘要
Objective To develop and validate a prognostic model for predicting all‐cause mortality in patients with antisynthetase syndrome (ASyS). Methods This retrospective study included 1,194 patients with ASyS from three independent institutions in China. The Cox proportional hazards (CPH) method and random survival forest (RSF) algorithm were used for developing a mortality risk prediction model in the derivation cohort (n = 763). The optimal model was simplified into a scoring system and validated in an external cohort of 431 patients from two institutions. Results The model constructed using the CPH method in the training cohort incorporated five prognostic factors: age at onset, lactate dehydrogenase, albumin, respiratory failure, and neutrophil‐to‐lymphocyte ratio. This model demonstrated better performance than the model developed using the RSF algorithm in the internal validation cohort and was subsequently transformed into a simplified scoring system, termed the ALARN score. The ALARN model achieved time‐dependent areas under the receiver operating characteristic curves of 0.914 (95% confidence interval [CI] 0.866–0.955), 0.867 (95% CI 0.829–0.906), 0.839 (95% CI 0.789–0.885), and 0.854 (95% CI 0.789–0.909) for predicting 1‐, 3‐, 5‐, and 10‐year mortality, respectively. Moreover, patients were effectively stratified into low‐, intermediate‐, and high‐risk groups (ALARN scores of 0–2, 3–5, and 6–8, respectively) with significantly different survival outcomes (log‐rank P < 0.0001). Internal and external validation confirmed the robustness of the ALARN score in predicting overall mortality in ASyS. Conclusion The ALARN score incorporates five readily available clinical parameters and provides a simple, practical tool for predicting mortality risk in patients with ASyS.
科研通智能强力驱动
Strongly Powered by AbleSci AI